The impact of zidovudine compared with didanosine on health status and functioning in persons with advanced HIV infection and a varying duration of prior zidovudine therapy

Antiviral Therapy

Volumn 1, Issue 1, 1996, Pages 21-32

  Bozzette, Samuel A ^a,b   Kanouse, David E ^a   Duan, Naihua ^a   Berry, Sandra ^a   Richman, Douglas D ^b,c  

^a RAND CORPORATION   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DIDANOSINE; ZIDOVUDINE;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; SICKNESS IMPACT PROFILE; SURVIVAL; TIME; TREATMENT OUTCOME;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DIDANOSINE; FEMALE; HIV INFECTIONS; HUMANS; MALE; SEVERITY OF ILLNESS INDEX; SICKNESS IMPACT PROFILE; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME; ZIDOVUDINE;

EID: 0029677208     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Berry SH, Bozzette SA, Hays RD, Stewart A & Kanouse DE. Measuring patient reported health status and experience in advanced HIV disease: the HIV-PARSE survey instrument. Health Sciences Program, RAND, Santa Monica, CA. 1994. MR-342-NIAID.
2. Bozzette SA, Duan N, Berry S & Kanouse DE. Analytic difficulties in applying quality of life outcomes to clinical trials of therapy for HIV Disease. Psychology and Health 1994a; 9:143-156.
3. Bozzette SA, Hays RD, Berry SH & Kanouse DE. A perceived health index for use in persons with advanced HIV disease: derivation, reliability, and validity. Medical Care 1994b; 32(7):716-731.
4. Bozzette SA, Kanouse DE, Berry S & Duan N. Health status and function with zidovudine or zalcitabine as initial therapy for advanced HIV Disease: A randomized controlled trial. Journal of the American Medical Association 1995; 273:295-301.
5. Bozzette SA, Kanouse DE, Berry SH, Mazel R, Stewart A, Hays R & NIAID ACTG. Measuring health status in advanced HIV disease: relationship of comprehensive measures to clinical indicators of illness. VII International Conference on AIDS, Florence, Italy, 16-21 June 1991. Abstract WB 2447.
6. Cooley TP, Kunches LM, Saunders CA, Ritter JK, Perkins CJ, McLaren C, McCaffrey RP & Liebman HA. Once daily administration of 2′,3′-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. Results of a Phase I trial. New England Journal of Medicine 1990; 322:1340-1345.
7. Croog SH, Levine S, Testa MA, Brown B, Bulpitt CJ, Jenkins CD, Klerman GL & Williams GH. The effects of antihypertensive therapy on the quality of life. New England Journal of Medicine 1986; 314:1657-1664.
8. Dolin R, Amato DA, Fischl MA, Pettinelli C, Beltangady M, Liou SH, Brown MJ, Cross AP, Hirsch MS, Hardy WD, Mildvan D, Blair DC, Powderly WG, Para MF, Fife KH, Steigbigel RT, Smaldone L & ACTG. Zidovudine compared with didanosine in patients with advanced HIV type 1 infection and little or no previous experience with zidovudine. Archives of Internal Medicine 1995; 155:961-974.
9. Duan N, Manning WG, Morris CN & Newhouse JP. A comparison of alternative models for the demand for medical care. Journal of Business and Economic Statistics 1983; 1:115-126.
10. Fischl MA, Richman DD, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL, Leedom JM, Groopman JE, Mildvan D, Schooley RT, Jackson GG, Durack DT, King D & ACTG. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. New England Journal of Medicine 1987; 317:185-191.
11. Fisher RA. In The design of experiments 9th Edn. 1971; 21: pp44-49. New York: Hafner Press.
12. Hays RD & Shapiro MF. An overview of generic health-related quality-of-life measures for HIV research. Quality of Life Research 1992; 1:91-97.
13. Kahn JO, Lagakos SW, Richman DD, Cross A, Pettinelli C, Liou SH, Brown M, Volberding PA, Crumpacker CS, Beall G, Sacks HS, Merigan TC, Beltangady M, Smaldone L, Dolin R & NIAID & ACTG. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. New England Journal of Medicine 1992; 327:581-587.
14. Kaplan RM, Anderson JP, Wu AW, Mathews WC, Kozin F & Wrenstein P. The quality of well-being scale. Applications in AIDS, cystic fibrosis, and arthritis. Medical Care 1989; 27 (suppl. 3):S27-43.
15. Lambert JS, Seidlin M, Reichman R, Plank CS, Laverty M, Morse GD, Knupp C, McLaren C, Pettinelli C, Valentine FT & Dolin R. 2′,3′-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. A Phase I trial. New England Journal of Medicine 1990; 322:1333-1340.
16. Lehmann EL. In Nonparametrics: statistical methods based on ranks. 1975; 1(7E): p43;
17. Lehmann EL. In Nonparametrics: statistical methods based on ranks. 1975; 2(70): p106. San Francisco: Holden-Day.
18. Lubeck DP & Fries JF. Changes in quality of life among persons with HIV infection. Quality of Life Research 1992; 1:359-366.
19. Moore RD, Hidalgo J, Sugland BW & Chaisson RE. Zidovudine and the natural history of the acquired immunodeficiency syndrome. New England Journal of Medicine 1991; 324: 1412-1416.
20. Schwartz D, Flamant R & Lellouch J. In Clinical trials. 1980. London: Academic Press.
21. Stewart AL, Sherbourne CD, Hays RD, Wells KB, Nelson EC, Kamberg CJ, Rogers WH, Berry SH & Ware JE. Summary and discussion of MOS measures. In Measuring functioning and well-being: the medical outcomes study approach. Edited by AL Stewart & JE Ware. 1992; pp345-371. Durham, KC: Duke University Press.
22. Wachtel TW, Piette J, Mor V, Stein M, Fleishman J & Carpenter C. Quality of life in persons with human immunodeficiency virus infection: measurement by the medical outcomes study instrument. Annals of Internal Medicine 1992; 116:129-137.
23. Wu AW, Mathews WC, Brysk LT, Atkinson JH, Grant I, Abramson I, Kennedy CJ, McCutchan JA, Spector SA & Richman DD. Quality of life in a placebo-controlled trial of zidovudine in patients with AIDS and AIDS-related complex. Journal of Acquired Immune Deficiency Syndromes 1990; 3:683-690.
24. Wu AW, Rubin HR, Mathews WC, Brysk LM, Bozzette SA, Hardy WD, Atkinson JH, Grant I, Spector SA, McCutchan JA et al. Functional status and well-being in a placebo-controlled trial of zidovudine in early symptomatic HIV Infection. Journal of Acquired Immune Deficiency Syndromes 1993; 6:452-458.
25. Wu AW, Rubin HR, Mathews WC, Ware Jr JE, Brysk LT, Hardy WD, Bozzette SA, Spector SA & Richman DD. A health status questionnaire using 30 items from the medical outcomes study. Preliminary validation in persons with early HIV infection. Medical Care 1991; 29:786-798.
26. Yarchoan R, Mitsuya H, Thomas RV, Pluda JM, Hartman NR, Perno CF, Marczyk KS, Allain JP, Johns DG & Broder S. In vivo activity against HIV and favourable toxicity profile of 2′,3′-dideoxyinosine. Science 1989; 245:412-415.
27. Yarchoan R, Pluda JM, Thomas RV, Mitsuya H, Brouwers P, Wyvill KM, Hartman N, Johns DG & Broder S. Long-term toxicity/activity profile of 2′,3′-dideoxyinosine in AIDS or AIDS-related complex. Lancet 1990; 336:526-529.